INS and metabolic dysfunction-associated steatotic liver disease: The same trend was observed for insulin, except in the moderate NAFLD group at the third (−4.09 95%CI −7.42; −0.76) and twelfth months (−5.33 95%CI 9.59;−1.07) and for Homa-IR in the moderate NAFLD group at the twelfth month (−1.58 95%CI −2.90;−0.26).